Published on
September 3, 2025
In the media
ÃÛÌÒTV x Innovate UK: Making cancer cells visible to the immune system
About ÃÛÌÒTV Therapeutics
â€
ÃÛÌÒTV Therapeutics is a clinical-stage biotech company advancing novel antigen modulation ÃÛÌÒTVs for cancer and autoimmune diseases.
â€
The company’s first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.
â€
ÃÛÌÒTV’s oncology ÃÛÌÒTV (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating durable clinical responses across multiple tumor types. The company’s autoimmunity ÃÛÌÒTV (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.
â€
ÃÛÌÒTV is headquartered in Oxford, UK.
â€
More information: Website |
â€
Media enquiries
Patrick White, Head of Communications
â€
